Stock Update (NYSE:ABBV): AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease

[PR Newswire] – COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA ® (adalimumab) is effective in reducing common clinical . . . → Read More: Stock Update (NYSE:ABBV): AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease Similar Articles: Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients Merck & Co Inc (NYSE:MRK) | U.S. FDA panel: data support safety, efficacy of Merck allergy drug Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Sobi’s partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting